Beta Amyloid News and Research RSS Feed - Beta Amyloid News and Research

Eli Lilly, AstraZeneca begin AZD3293 Phase II/III study for treatment of early Alzheimer's disease

Eli Lilly, AstraZeneca begin AZD3293 Phase II/III study for treatment of early Alzheimer's disease

Eli Lilly and Company and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease. [More]
DTI may play role in assessing brain damage in early Alzheimer's disease

DTI may play role in assessing brain damage in early Alzheimer's disease

Changes in brain connections visible on MRI could represent an imaging biomarker of Alzheimer's disease, according to a new study presented today at the annual meeting of the Radiological Society of North America (RSNA). [More]
New culture system confirms amyloid theory, can revolutionize drug discovery for Alzheimer's disease

New culture system confirms amyloid theory, can revolutionize drug discovery for Alzheimer's disease

An innovative laboratory culture system has succeeded, for the first time, in reproducing the full course of events underlying the development of Alzheimer's disease. [More]
Research findings could help explain how some people stave off dementia

Research findings could help explain how some people stave off dementia

The human brain is capable of a neural workaround that compensates for the buildup of beta-amyloid, a destructive protein associated with Alzheimer's disease, according to a new study led by researchers at the University of California, Berkeley. [More]
Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

Lilly, AstraZeneca partner to co-develop and commercialize potential Alzheimer's disease treatment

Eli Lilly and Company and AstraZeneca today announced an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease. [More]
Study shows bryostatin plays key role in slowing or reversing Alzheimer's disease

Study shows bryostatin plays key role in slowing or reversing Alzheimer's disease

Neurotrope, Inc. (OTCQB: NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen, Ph.D.; Jarin Hongpaisan, Ph.D.; Chol S. Lim, Ph.D.; Thomas J. Nelson, Ph.D., and; Dr. Daniel L. Alkon, each of the Blanchette Rockefeller Neurosciences Institute (BRNI), provide further indication of the role that protein kinase C epsilon (PKCe) may play in the potential treatment of Alzheimer's disease (AD). [More]
People who develop depression, MCI after age 65 are more vulnerable for accelerated brain aging

People who develop depression, MCI after age 65 are more vulnerable for accelerated brain aging

People who develop depression and mild cognitive impairment (MCI) after age 65 are more likely to have biological and brain imaging markers that reflect a greater vulnerability for accelerated brain aging, according to a study conducted by researchers at the University of Pittsburgh School of Medicine. The findings were published online in Molecular Psychiatry. [More]
PLXNA4 gene may increase risk of developing Alzheimer's disease

PLXNA4 gene may increase risk of developing Alzheimer's disease

Researchers from Boston University School of Medicine report variants in a new gene, PLXNA4, which may increase the risk of developing Alzheimer's disease (AD). The discovery of this novel genetic association may lead to new drug treatment options that target PLXNA4 specifically. [More]
Noninvasive optical imaging device helps to detect changes linked with Alzheimer's disease

Noninvasive optical imaging device helps to detect changes linked with Alzheimer's disease

A noninvasive optical imaging device developed at Cedars-Sinai can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer's disease, according to preliminary results from investigators conducting a clinical trial in Australia. [More]
Eye exam for beta-amyloid correlates with levels in brain, detects people with Alzheimer's

Eye exam for beta-amyloid correlates with levels in brain, detects people with Alzheimer's

A decreased ability to identify odors might indicate the development of cognitive impairment and Alzheimer's disease, while examinations of the eye could indicate the build-up of beta-amyloid, a protein associated with Alzheimer's, in the brain, according to the results of four research trials reported today at the Alzheimer's Association International Conference- 2014 (AAIC- 2014) in Copenhagen. [More]
BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

BrightFocus Foundation, a nonprofit organization funding cutting-edge, innovative research on Alzheimer's disease and the vision diseases of glaucoma and macular degeneration, today announced the recipients of new research grant awards, offered to 55 scientists in 19 U.S. states, the District of Columbia, and five foreign countries. [More]
EMA CHMP recommends marketing authorization for GE's VIZAMYL for PET imaging to detect beta amyloids

EMA CHMP recommends marketing authorization for GE's VIZAMYL for PET imaging to detect beta amyloids

GE Healthcare today announced the receipt of a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. This opinion recommends the granting of a marketing authorisation for VIZAMYL (Flutemetamol F18 injection), a radiopharmaceutical medicinal product indicated for Positron Emission Tomography imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment. [More]
Late-life depression could become major risk factor for developing Alzheimer's

Late-life depression could become major risk factor for developing Alzheimer's

Many people develop depression in the latest stages of life, but until now doctors had no idea that it could point to a build up of a naturally occurring protein in the brain called beta-amyloid, a hallmark of Alzheimer's disease. [More]
GE Healthcare announces commercial availability of new Alzheimer’s diagnostic tool

GE Healthcare announces commercial availability of new Alzheimer’s diagnostic tool

GE Healthcare today announced the first seven markets where Vizamyl (Flutemetamol F18 injection), a radioactive diagnostic agent approved by the FDA will be available. Late in the second quarter of 2014, Vizamyl will be available to imaging centers near East Rutherford, NJ, Woburn, MA, Beltsville, MD, East Lansing, MI, Dallas, TX, Phoenix, AZ and Colton, CA. [More]
NeuroPhage engineers series of molecules with potential to treat most neurodegenerative diseases

NeuroPhage engineers series of molecules with potential to treat most neurodegenerative diseases

​Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases. [More]
Research sheds new light onto possible causes of sudden infant death syndrome

Research sheds new light onto possible causes of sudden infant death syndrome

Research at the University of Adelaide has shed new light onto the possible causes of sudden infant death syndrome (SIDS), which could help to prevent future loss of children's lives. [More]
Researchers identify eight new active molecules against Alzheimer

Researchers identify eight new active molecules against Alzheimer

Researchers of the Unit of Medicine Design and Molecular Topology (Department of Physics Chemistry) of the University of Valencia have discovered eight new active molecules against Alzheimer by a novel mechanism of action, different to the currently used medicines. The work has just been published in the "Plos One" magazine. [More]
New lab at the Nencki Institute conducts research on neurodegenerative diseases

New lab at the Nencki Institute conducts research on neurodegenerative diseases

The Laboratory of Preclinical Studies of Higher Standard, the newest lab of the Neurobiology Center at the Nencki Institute in Warsaw, Poland, will conduct basic research aimed to explain molecular mechanisms responsible for neurodegenerative diseases. [More]
Caffeine has positive effect on tau deposits in Alzheimer's disease

Caffeine has positive effect on tau deposits in Alzheimer's disease

As part of a German-French research project, a team led by Dr. Christa E. Müller from the University of Bonn and Dr. David Blum from the University of Lille was able to demonstrate for the first time that caffeine has a positive effect on tau deposits in Alzheimer's disease. [More]
Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results. [More]